A wide array of drugs that are generally effective in reducing the risk of fracture and have a well-tolerated side-effect profile are available for the treatment of osteoporosis. Further, oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of their widespread generic availability and physician familiarity. Branded agents—Amgen’s Prolia, Eli Lilly’s Forteo, and Radius Health’s Tymlos—are reserved for use in the later lines of therapy, primarily because of their higher price. Osteoporosis Treatment Algorithm presents insights into the treatment practice of a disease where brands compete for market share in second and later lines of therapy and combination use is minimal.
- What patient share do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients? What are the quarterly trends in prescribing among recently treated and new diagnosed osteoporosis patients?
- How have Prolia, Forteo, and Tymlos been integrated into the treatment algorithm?
- What proportion of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly?
- What percentage of patients progress to later lines of therapy within one year of diagnosis? ·
- What percentage of osteoporosis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
- What are the product-level compliance and persistency rates among drug-treated patients with osteoporosis?